Inactive Instrument

Elanix Biotechnologies AG

Equities

ELN

DE000A0WMJQ4

Biotechnology & Medical Research

Elanix Biotechnologies AG Announces Resignation of Jürgen Kullmann from the Supervisory Board

February 14, 2019 at 04:22 am EST

The chairman of the supervisory board of Elanix Biotechnologies AG, Mr. Jürgen Kullmann, has notified the CEO that he will resign from office with immediate effect for health reasons and retire from the Supervisory Board.

Latest news about Elanix Biotechnologies AG

Elanix Biotechnologies AG Announces Executive Changes	20-02-27	CI
Elanix Biotechnologies Ag Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-19	CI
Anja Silling acquired 12.85% stake in Elanix Biotechnologies AG (DB:ELN) from Lee-Ann Laurent-Applegate for €1 million.	19-05-12	CI
Elanix Biotechnologies Ag Announces Nomination of the Chairman of the Supervisory Board, the Vice Chairman and Members of the Board	19-04-18	CI
Elanix Biotechnologies AG Announces Resignation of Jürgen Kullmann from the Supervisory Board	19-02-14	CI
Elanix Biotechnologies AG Announces Change in Supervisory Board	19-02-07	CI
Elanix Plans To Sell Shares Of Company	18-11-23	CI
Elanix Biotechnologies AG (DB:ELN) cancelled the acquisition of Inno 4 Cell AG.	18-08-21	CI
Elanix Biotechnologies AG announced that it has received €0.870298 million in funding	18-06-10	CI
Elanix Biotechnologies AG Appoints Egon Minar to the Joint Role of Chief Operating Officer and Chief Financial Officer	18-05-29	CI
Elanix Biotechnologies AG announced that it expects to receive €0.870298 million in funding	18-05-27	CI
Elanix Biotechnologies AG signs an Agreement with MedBioSante	18-05-23	CI
Elanix Biotechnologies AG announced that it expects to receive €2.5 million in funding from Yorkville Advisors Global LP	18-04-29	CI
Elanix Biotechnologies AG announced that it expects to receive €11 million in funding	18-02-13	CI
Elanix Biotechnologies AG announced that it has received €1.125071 million in funding	18-02-13	CI
Elanix Biotechnologies AG announced a financing transaction	17-12-11	CI
Elanix Biotechnologies Enters into Co-Development Agreement with Dermacon	17-12-03	CI
Elanix Biotechnologies AG Reports Audited Consolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Earnings Guidance for the Financial Year 2017	17-09-29	CI
Elanix Biotechnologies AG (DB:ELN) agreed to acquire Inno 4 Cell AG.	17-08-21	CI
Transwell Biotech Co., Ltd. Starts First Clinical Study with Progenitor Cell Treatment for Skin Graft Wounds	17-07-20	CI
Elanix Biotechnologies AG Starts EU Commercialization of GYNrepair Cream for Women’s Intimate Relief	17-05-31	CI
Elanix Biotechnologies AG Signs an Agreement with Apraxon GmbH	17-04-28	CI
Elanix Biotechnologies AG Signs Agreement with Apraxon to Establish European Logistics Center	17-04-21	CI
Elanix Biotechnologies AG Announces Non-Binding Letter of Intent with Oxford Mestar Ltd. in Regard to Setting Up JV to Market Gynrepair in China	16-11-22	CI
Elanix Biotechnologies AG announced that it has received €1.22 million in funding	16-08-10	CI

Chart Elanix Biotechnologies AG

Duration

Period

More charts

Company Profile

Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research